|
WO2016131128A1
|
|
Humanized ebola antibodies and uses thereof
|
|
WO2016008047A1
|
|
Cyclic peptide vaccination for treatment of amyloid beta-related disorders
|
|
EP3102611A1
|
|
Humanized beta-amyloid binding molecules and uses thereof
|
|
IL231661D0
|
|
Clostridium difficile antibodies
|
|
CA2845884A1
|
|
Clostridium difficile antibodies
|
|
WO2013013323A1
|
|
Staphlococcus aureus alpha-hemolysin antibodies
|
|
EP2661500A2
|
|
Clostridium difficile antigens
|
|
CA2610791A1
|
|
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
|
WO2007009208A1
|
|
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
|
WO2005069717A2
|
|
The use os anti-rh antibodies for treating acute thrombocytopenia associated with dengue hemorrhagic fever, hepatitis c and other microbial infections
|
|
EP1663296A1
|
|
Liquid human growth hormone formulation containing polyethylene glycol
|
|
WO2004009627A1
|
|
Pegylated erythropoietic compounds
|
|
IL158297D0
|
|
Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
|
|
CA2462531A1
|
|
Phagemid display system
|
|
CA2406593A1
|
|
Rhamm peptide conjugates
|
|
CA2280061A1
|
|
Method of prevention and treatment of multiple sclerosis with varicella zoster immune globulin
|
|
CA2320104A1
|
|
Method for the prevention and treatment of a type i hypersensitivity disorder
|
|
US6271344B1
|
|
Enhanced affinity hyaluronan binding peptides
|
|
EP0973549A2
|
|
Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
|
|
US6127144A
|
|
Method for expression of proteins in bacterial host cells
|
